BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#275 of 347

Edward Tenthoff

Piper Sandler · Equity Research Analyst
EstablishedRating since 2020No new ratings since Jun 2025

Analyst rating accuracy & track record

Edward Tenthoff is an equity research analyst at Piper Sandler. Bullish Whales has scored 45 of their stock calls across 25 companies. Their picks beat their sector 27% of the time over the next 12 months, and their price targets were reached 29% of the time within a year.

Win % vs sector
27%
PT Hit % (12mo)
29%
Avg sector-excess
−16.2%
Scored calls
45
Tickers
25
Tier
Established

Track record

Bullish Whales has scored 45 of Edward Tenthoff's stock calls across 25 companies, dating back to 2020. Their rated stocks beat their own sector 27% of the time over the next 12 months. On a typical call, a Tenthoff pick returned −16.2% more than its sector over the following year.

Of the scored calls, 45 were bullish (Buy). Most of their coverage sits in Unknown. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
BMEABiomea Fusion Inc
Buy$7.00Jun 2025−67.2%Miss
FULCFulcrum Therapeutics Inc
Buy$9.00May 2025−14.0%Hit
IPSCCentury Therapeutics Inc
Buy$2.00Mar 2025+335.2%Hit
MESOMesoblast Ltd
Buy$24.00Feb 2025−18.9%Miss
IPSCCentury Therapeutics Inc
Buy$4.00Dec 2024−16.2%Miss
MESOMesoblast Ltd
Buy$15.00Dec 2024+18.9%Hit
XNCRXencor Inc
Buy$30.00Dec 2024−46.9%Miss
TPSTTempest Therapeutics Inc
Buy$5.00Nov 2024−37.3%Miss
CAMPCAMP4 THERAPEUTICS CORPORATION
Buy$18.00Nov 2024−54.4%Miss
CAPRCapricor Therapeutics Inc
Buy$35.00Oct 2024−66.1%Miss
STROSutro Biopharma
Buy$11.00Oct 2024−71.7%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$20.00Sep 2024+21.4%Miss
OPKOpko Health Inc
Buy$3.00Sep 2024−4.0%Miss
MRNAModerna Inc
Buy$115.00Sep 2024−54.0%Miss
CUECue Biopharma
Buy$3.00Jul 2024+35.1%Miss
MESOMesoblast Ltd
Buy$11.00Jul 2024+109.9%Hit
OPKOpko Health Inc
Buy$3.00Jul 2024−0.1%Miss
GLUEMonte Rosa Therapeutics Inc
Buy$16.00Jun 2024+19.9%Miss
TPSTTempest Therapeutics Inc
Buy$8.00Jun 2024−66.2%Miss
IPSCCentury Therapeutics Inc
Buy$12.00Jun 2024−73.0%Miss
FATEFate Therapeutics Inc
Buy$6.00Jun 2024−57.8%Miss
IPSCCentury Therapeutics Inc
Buy$9.00Apr 2024−87.9%Miss
CUECue Biopharma
Buy$8.00Apr 2024−59.7%Miss
OPKOpko Health Inc
Buy$5.00Apr 2024+21.9%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$20.00Mar 2024−82.4%Miss
MISTMilestone Pharmaceuticals Inc
Buy$5.00Mar 2024+32.4%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$12.00Feb 2024−48.8%Hit
CUECue Biopharma
Buy$8.00Nov 2023−50.0%Miss
LIFEEvolve Global Healthcare Enhanced Yield Fund Hedged Units
Buy$13.00Apr 2023−21.9%Hit
TPSTTempest Therapeutics Inc
Buy$6.00Mar 2023+151.5%Hit
GRTXGalera Therapeutics Inc
Buy$6.00Feb 2023−117.1%Miss
XFORX4 Pharmaceuticals Inc
Buy$3.00Dec 2022−20.6%Miss
CUECue Biopharma
Buy$7.00Nov 2022−22.3%Miss
NXTCNextCure  Inc
Buy$6.00Nov 2022−30.2%Miss
MCRBSeres Therapeutics Inc
Buy$9.00Sep 2022−55.5%Hit
MESOMesoblast Ltd
Buy$7.00Sep 2022−52.4%Miss
PRTCPureTech Health PLC
Buy$44.00Aug 2022−25.7%Miss
ELOXEloxx Pharmaceuticals Inc
Buy$1.50May 2022−42.8%Hit
NXTCNextCure  Inc
Buy$13.00May 2022−49.2%Miss
MCRBSeres Therapeutics Inc
Buy$7.00May 2022+65.5%Hit
APVOAptevo Therapeutics Inc
Buy$20.00May 2022−6.8%Miss
GLUEMonte Rosa Therapeutics Inc
Buy$21.00May 2022−35.1%Miss
MISTMilestone Pharmaceuticals Inc
Buy$10.00Apr 2022−45.8%Miss
SYBXSynlogic Inc
Buy$9.00Sep 2021−67.6%Miss
APVOAptevo Therapeutics Inc
Buy$69.00Nov 2020−22.1%Miss
Go to

Edward Tenthoff: analyst track record FAQ

Is Edward Tenthoff a good stock analyst?

Yes, by track record. Edward Tenthoff ranks number 275 of 347 of the analysts Bullish Whales scores, with a BW Score of 1 out of 100. Past results do not guarantee future ones.

What is Edward Tenthoff's win rate?

Edward Tenthoff's win rate is 27%. Across 45 scored calls, their rated stocks beat their sector 27% of the time over the next 12 months. On a typical call they returned −16.2% more than the sector.

What stocks and sectors does Edward Tenthoff cover?

Edward Tenthoff covers 25 companies, with the most coverage in Unknown. See the ratings table above for every scored call and its outcome.

Are Edward Tenthoff's price targets accurate?

Edward Tenthoff's price targets are reached within 12 months 29% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Edward Tenthoff's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Edward Tenthoff rank among Wall Street analysts?

Edward Tenthoff ranks number 275 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30